Explore Cagrilintide + Semaglutide (CagriSema) dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Cagrilintide + Semaglutide, known in clinical development as CagriSema (Novo Nordisk), pairs the long-acting amylin analog cagrilintide with the GLP-1 receptor agonist semaglutide in a single once-weekly co-formulation, studied in the REDEFINE program for obesity and type 2 diabetes. The combination targets two complementary satiety pathways at once. This data shows the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting a Cagrilintide + Semaglutide blend.
Cagrilintide + Semaglutide (CagriSema) is a research-grade blend of an amylin analog (cagrilintide) and a GLP-1 agonist (semaglutide), most often sourced for weight-management and metabolic research. Novo Nordisk's pharmaceutical version completed Phase 3 obesity trials but is not yet FDA-approved. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
CagriSema combines two complementary appetite-regulating pathways in a single weekly subcutaneous injection. The semaglutide arm produces standard GLP-1 effects (slowed gastric emptying, glucose-dependent insulin release, hypothalamic appetite suppression). The cagrilintide arm activates amylin receptors and calcitonin-receptor heterodimers in the area postrema and hypothalamus, reinforcing satiety and slowing gastric emptying through a complementary brainstem-mediated pathway. The combination is rationalised by amylin and GLP-1 working through non-overlapping receptor systems.
8% on cagrilintide alone, in adults with obesity but without T2D — confirming meaningful additive benefit over either component, though the headline figure undershot Novo's pre-trial expectation of ~25%. 0% range. , Lancet 2021) established the dose-response profile. See also the standalone Cagrilintide and Semaglutide entries for component-level detail.
Cagrilintide + Semaglutide has a reported half-life of ~7 days (both components), and the dose intervals researchers model most often fall around once weekly. Both parts are long-acting (about a week each), so once-weekly dosing builds to a steady level over roughly 5 weeks. It is catalogued under Weight Loss on WPA.
38 Cagrilintide + Semaglutide reconstitution calculations have been logged by the WPA community. The most common dose entered is 2.4mg (5 calculations). The median dose across all sessions is 750mcg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (17 sessions). The most common dosing frequency is once weekly (2 logged protocols), followed by daily (7x/week) (1).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.